FindTrial
Sign In

Taselisib

DRUG8 trials

Sponsors

SWOG Cancer Research Network, Genentech, Inc., Hoffmann-La Roche, Otto Metzger, MD, Vanderbilt-Ingram Cancer Center

Conditions

Advanced LymphomaAdvanced Malignant Solid NeoplasmBladder CarcinomaBreast CancerBreast CarcinomaCervical CarcinomaColon CarcinomaColorectal Carcinoma

Phase 1

Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer
CompletedNCT02390427
Otto Metzger, MDMetastatic Breast Cancer, Recurrent Breast Cancer
Start: 2015-04-20End: 2024-07-31Updated: 2024-10-02
Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer
TerminatedNCT02457910
Vanderbilt-Ingram Cancer CenterEstrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative +4
Start: 2015-06-30End: 2022-08-08Updated: 2022-08-22

Phase 2

A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)
CompletedNCT02273973
Genentech, Inc.Breast Cancer
Start: 2014-11-12End: 2017-03-13Updated: 2018-05-21
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Active, not recruitingNCT02465060
National Cancer Institute (NCI)Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma +49
Start: 2015-08-17End: 2026-12-31Target: 6452Updated: 2026-04-03
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
CompletedNCT02785913
SWOG Cancer Research NetworkRecurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma
Start: 2014-11-30End: 2019-11-30Updated: 2020-10-23
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
Active, not recruitingNCT04439175
National Cancer Institute (NCI)Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm +3
Start: 2016-02-25End: 2026-03-19Updated: 2025-11-18

Phase 3

A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy
TerminatedNCT02340221
Hoffmann-La RocheBreast Cancer
Start: 2015-04-09End: 2021-06-29Updated: 2022-07-12

Unknown Phase

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
CompletedNCT02154490
SWOG Cancer Research NetworkRecurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Start: 2014-07-08End: 2022-04-15Updated: 2023-06-01

Related Papers

Phase II Study of Vismodegib in Patients With <i>SMO-</i> or <i>PTCH1</i>-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T.
2025-10-09
Comprehensive genomic profiling of matched ctDNA and tissue from patients with less common cancers enrolled in but not eligible for a treatment arm of the NCI-MATCH trial.
Journal of Clinical Oncology2025-05-281 citations
Quantitative characterization of the effects of fulvestrant alone or in combination with taselisib (PI3Kinase inhibitor) on longitudinal tumor growth in patients with estrogen receptor-positive, HER2-negative, PIK3CA-mutant, advanced or metastatic breast cancer.
2024-06-27
Molecular profiling of plasma from matched NCI-MATCH gynecological cancers.
Journal of Clinical Oncology2024-06-011 citations
Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial
The Oncologist2024-05-306 citations
10P PIK3CA mutation and response to neoadjuvant taselisib and endocrine therapy: A biomarker study of the LORELEI trial
ESMO Open2024-05-01
Abstract B007: Concordance between tumor tissue and plasma genotyping in NCI-MATCH Trial (EAY131)
Molecular Cancer Therapeutics2023-12-01
Revolutionizing cancer drug development: Harnessing the potential of basket trials.
2023-11-0720 citations
The NCI-MATCH trial: lessons for precision oncology.
2023-06-15103 citations
Phase II study of crizotinib in patients with <i>MET</i> amplification and <i>MET</i> exon 14 deletion: Results from NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocols C1 and C2.
Journal of Clinical Oncology2023-06-012 citations
Discovery of gene fusions in driver-negative NCI-MATCH screening samples.
Journal of Clinical Oncology2023-06-011 citations
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial
Nature Medicine2023-04-14244 citations
Abstract 5559: Exploratory analysis of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) <i>PIK3CA</i> mutated (mut) advanced breast cancer (aBC) treated with taselisib (TAS) and/or fulvestrant (FUL) reveals increased <i>CCNE2</i> expression with poor outcome to placebo (PBO) + FUL but not TAS + FUL in SANDPIPER
Cancer Research2023-04-04
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
Clinical Cancer Research2023-01-2055 citations
Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology
npj Precision Oncology2022-10-2715 citations
Abstract 2438: Determining the role of non-mutated C-Raf kinase in metastatic disease
Cancer Research2022-06-15
Abstract 5165: The genomic landscape and prognostic implications of somatic alterations in patients (pts) with ER+, HER2-, PIK3CA mutated (mut) advanced breast cancer treated with taselisib and fulvestrant
Cancer Research2022-06-15
Abstract 5026: Dynamic changes in circulating protein levels reveal an association between ipilimumab and nivolumab combination treatment (SWOG Lung-MAP S1400I trial) with outcomes in squamous cell lung cancer
Cancer Research2022-06-15
Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.
2022-06-077 citations
Phase II study of vismodegib in patients with <i>SM</i>O or <i>PTCH1</i> mutated tumors: Results from NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol T.
Journal of Clinical Oncology2022-06-013 citations

49 more papers not shown